Skip to main content
Top
Published in: Annals of Hematology 8/2003

01-08-2003 | Case Report

Testicular plasmacytoma with bone dissemination without medullary plasmacytosis

Authors: T. Y. Hou, M. S. Dai, W. Y. Kao

Published in: Annals of Hematology | Issue 8/2003

Login to get access

Abstract

A 34-year-old man was diagnosed as having solitary testicular plasmacytoma. He had received palliative radiotherapy, several combined chemotherapies including CHOP chemotherapy (vincristine, cyclophosphamide, Adriamycin, and prednisone), MP (melphalan and prednisone) and M-2 protocol (melphalan, prednisone, vincristine, carmustine, and cyclophosphamide), and interferon therapy as 3 million units subcutaneous injection three times a week for 1 year. Extensive bone plasmacytoma developed 7 years later without bone marrow involvement. We suggest that early use of combined chemoradiotherapy and high-dose chemotherapy with autologous stem cell support should be investigated in patients with testicular plasmacytoma with dissemination.
Literature
1.
go back to reference Piero G, Michele C, Alessandro P, Giuseppe A, Catia B, Stefano N, et al. (2000) Clinical outcome of extramedullary plasmacytoma. Haematologica 85:47–51 Piero G, Michele C, Alessandro P, Giuseppe A, Catia B, Stefano N, et al. (2000) Clinical outcome of extramedullary plasmacytoma. Haematologica 85:47–51
2.
go back to reference Holland J, Trenkner DA, Wasserman TH, Fineberg B (1992) Plasmacytoma treatment results and conversion to myeloma. Cancer 69:1513-1517CrossRefPubMed Holland J, Trenkner DA, Wasserman TH, Fineberg B (1992) Plasmacytoma treatment results and conversion to myeloma. Cancer 69:1513-1517CrossRefPubMed
3.
go back to reference Gulbrandsen N, Wisloff F, Nord E, Lenhoff S, Hjorth M, Westin J (2001) Nordic Myeloma Study Group: cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol 66:328–336CrossRefPubMed Gulbrandsen N, Wisloff F, Nord E, Lenhoff S, Hjorth M, Westin J (2001) Nordic Myeloma Study Group: cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol 66:328–336CrossRefPubMed
4.
go back to reference Kyle RA (2001) Multiple myeloma. Diagnostic challenges and standard therapy. Semin Hematol 38:11–14CrossRefPubMed Kyle RA (2001) Multiple myeloma. Diagnostic challenges and standard therapy. Semin Hematol 38:11–14CrossRefPubMed
5.
go back to reference Chica G, Johnson DE, Ayala AG (1978) Plasmacytoma of testis presenting as primary testicular tumor. Urology 11:90–92CrossRefPubMed Chica G, Johnson DE, Ayala AG (1978) Plasmacytoma of testis presenting as primary testicular tumor. Urology 11:90–92CrossRefPubMed
6.
go back to reference Carson CP, Ackerman LV, Maltby JD (1955) Plasma cell myeloma: a clinical pathologic and roentgenologic review of 9 cases. Am J Clin Pathol 25:849–888CrossRefPubMed Carson CP, Ackerman LV, Maltby JD (1955) Plasma cell myeloma: a clinical pathologic and roentgenologic review of 9 cases. Am J Clin Pathol 25:849–888CrossRefPubMed
7.
go back to reference Dolin S, Dewar JP (1955) Extramedullary plasmacytoma. Am J Pathol 32:83 Dolin S, Dewar JP (1955) Extramedullary plasmacytoma. Am J Pathol 32:83
9.
go back to reference Gowing NFC (1964) Malignant lymphoma of the testis. In: Pathology of testicular tumors. Br J Urol 36 [Suppl]:84–94 Gowing NFC (1964) Malignant lymphoma of the testis. In: Pathology of testicular tumors. Br J Urol 36 [Suppl]:84–94
10.
12.
go back to reference Tetsuzo K, Toshihiko A, Yosuke M, Hiroyuki O, Tsukasa O, Toshio T (1980) Primary testicular plasmacytoma: a case report. Acta Med Okayama 34:315–322 Tetsuzo K, Toshihiko A, Yosuke M, Hiroyuki O, Tsukasa O, Toshio T (1980) Primary testicular plasmacytoma: a case report. Acta Med Okayama 34:315–322
13.
go back to reference Nelson T, Marvin JB, Clara RY, Joseph JS, Andrew S (1986) Plasmacytoma of the testis. J Urol 137:745-747 Nelson T, Marvin JB, Clara RY, Joseph JS, Andrew S (1986) Plasmacytoma of the testis. J Urol 137:745-747
14.
15.
go back to reference Tatsuo I, Satoshi S, Hiroshi A, Tsunetada Y, Takashi U, Fumihiko T, et al. (1995) Plasmacytoma of the testis. Urol Int 55:218–221CrossRef Tatsuo I, Satoshi S, Hiroshi A, Tsunetada Y, Takashi U, Fumihiko T, et al. (1995) Plasmacytoma of the testis. Urol Int 55:218–221CrossRef
16.
go back to reference Fischer C, Terpe HJ, Weidner W, Schulz A (1996) Primary plasmacytoma of the testis. Urol Int 56:263–265CrossRefPubMed Fischer C, Terpe HJ, Weidner W, Schulz A (1996) Primary plasmacytoma of the testis. Urol Int 56:263–265CrossRefPubMed
18.
go back to reference Suzuki K, Shioji Y, Morita T, Tokue A (2001) Primary testicular plasmacytoma with hydrocele of the testis. Int J Urol 8:139–140CrossRefPubMed Suzuki K, Shioji Y, Morita T, Tokue A (2001) Primary testicular plasmacytoma with hydrocele of the testis. Int J Urol 8:139–140CrossRefPubMed
Metadata
Title
Testicular plasmacytoma with bone dissemination without medullary plasmacytosis
Authors
T. Y. Hou
M. S. Dai
W. Y. Kao
Publication date
01-08-2003
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2003
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0672-7

Other articles of this Issue 8/2003

Annals of Hematology 8/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.